Nanoparticle-based biosensors to track drug efficacy
Glympse Bio, a Cambridge, Mass.-based startup, is developing nanoparticle-based biosensors meant to supplant traditional biopsies. The idea is to help drug makers gauge whether their drugs are improving a patient’s condition.
The company, which has raised more than $45 million in venture funding, will have its first biosensors tested in Gilead’s clinical trials for NASH, STAT’s Kate Sheridan writes. Its technology works by injecting patients with nanoparticles that interact with enzymes called proteases that signal how a disease is progressing.
No hay comentarios:
Publicar un comentario